A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
← catalyst calendarNCT06925542 · readout in 1,960 d
Sponsored by CRISPR Therapeutics (industry) · CRSP — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
80estimated
Sites
14
Countries
Germany, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-10 | actual | When the study began enrolling |
| Primary completion | 2031-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- SLE (Systemic Lupus)
- Lupus Erythematosus, Systemic
- Lupus Nephritis
- Systemic Sclerosis
- Inflammatory Myopathy, Idiopathic
- Myositis
- Diffuse Cutaneous Systemic Sclerosis
Intervention
- Biological: CTX112
Primary outcome
what the primary-completion date above is the date OFTo evaluate the safety of CTX112 in adult subjects with refractory autoimmune diseases, including SLE, SSc or IIM
measured From CTX112 infusion up to 28 days post-infusion
Permalink · CRSP's whole pipeline · Catalyst calendar · Every registered study · What changed